Drug Profile
Camidanlumab tesirine - ADC Therapeutics/Genmab
Alternative Names: ADCT-301; Cami; HuMax®-TAC-ADCLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator ADC Therapeutics; Genmab
- Developer ADC Therapeutics
- Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunoconjugates; Monoclonal antibodies; Pyrroles
- Mechanism of Action Cell death stimulants; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Acute myeloid leukaemia; Hodgkin's disease; Myelodysplastic syndromes; Myeloproliferative disorders
- Phase I Non-Hodgkin's lymphoma; Solid tumours
- No development reported Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 24 May 2023 ADC Therapeutics terminates a phase II trial in Acute myeloid leukaemia, Myelodysplastic syndromes and Myeloproliferative disorders (Second-line therapy or greater, In adults, In the elderly) in USA (IV) due to reallocation of all resources to the phase III program (NCT04639024)
- 28 Feb 2023 Camidanlumab tesirine - ADC Therapeutics/Genmab is available for licensing as of 06 Mar 2023. https://www.adctherapeutics.com/
- 19 Jan 2023 ADC Therapeutics completes phase II trial for Hodgkin's disease (Second-line therapy or greater, In adolescents, In adults, In the elderly) in US, Belgium, Canada, Czech Republic, France, Germany, Hungary, Italy, Poland, Spain, UK (IV) (NCT04052997) (EudraCT2018-002556-32)